

MeBN/02/Zof-AMI/001 (ZAAMIS)

ZAAMIS (Zofenopril After Acute Myocardial Infarction Study)

A multicenter, double-blind, randomized 2x2 factorial design study to compare the efficacy of early (<6 hours) versus late (24-48 hours) ACEinhibition and to compare the efficacy of Zofenopril and Lisinopril on oxidative reperfusion injury after a first acute anterior myocardial infarction:

This study has been completed. Results will be soon available in the "Results section"

Sponsor: Menarini Benelux SA/NV

Intervention: Zofenopril 30 mg twice daily

Condition: Acute Myocardial Infarction

This study is designed to assess the effects of the administration of **zofenopril, compared with lisinopril**, on oxidative stress. The efficacy of zofenopril and lisinopril will be primarily evaluated through the measurement, by peak urinary concentrations, of malonyldialdehyde. In addition, left ventricular function and remodeling and neurohormonal parameters will also be assessed.

Study type & design: multi-center, double blind, randomized, 2x2 factorial, parallel group study.

Main criteria for inclusion:

Subjects undergoing a primary percutaneous coronary intervention (PCI) for a first acute anterior myocardial infarction. Written informed consent for participation in the study.

Main criteria for exclusion:

Significant cardiac valve disease. Significant rhythm disorders. Use of ACE-inhibitors prior to myocardial infarction. Systolic BP < 100 mmHg.